MRNA:OTCQB-Marina Biotech Inc (USD)

COMMON STOCK | Biotechnology | OTCQB - U.S. Registered

Last Closing

USD 122.45

Change

-15.15 (-11.01)%

Market Cap

USD 0.02B

Volume

7.72M
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Marina Biotech Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of nucleic acid-based therapies to treat orphan diseases.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-06-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 119.56B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 114.65B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 35.29B
ARGX argenx NV ADR

N/A

USD 32.06B
BGNE BeiGene Ltd

N/A

USD 24.38B
RPRX Royalty Pharma Plc

N/A

USD 16.72B
UTHR United Therapeutics Corporatio..

N/A

USD 15.71B
SMMT Summit Therapeutics PLC

N/A

USD 15.35B
PCVX Vaxcyte Inc

N/A

USD 14.00B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 13.46B

ETFs Containing MRNA

MRN3:LSE Leverage Shares 3x Long M.. 300.18 % 0.00 %

N/A

USD 0.39M
MSGR 6.26 % 0.00 %

N/A

N/A
CURE:XETRA VanEck Genomics and Healt.. 5.70 % 0.00 %

N/A

N/A
HVAX:CA 4.95 % 0.00 %

N/A

N/A
BTEC:SW iShares Nasdaq US Biotech.. 4.67 % 0.00 %

N/A

N/A
BBH VanEck Biotech ETF 3.67 % 0.35 %

N/A

USD 0.45B
LS:CA 3.47 % 2.21 %

N/A

N/A
XNNV:XETRA Xtrackers MSCI Innovation.. 3.03 % 0.00 %

N/A

N/A
XNNS:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

N/A

N/A
XNNV:LSE Xtrackers MSCI Innovation.. 3.01 % 0.00 %

N/A

N/A
ASRP:XETRA BNP Paribas Easy ECPI Glo.. 2.69 % 0.00 %

N/A

N/A
2B70:F iShares NASDAQ US Biotech.. 2.48 % 0.00 %

N/A

USD 0.52B
2B70:XETRA iShares Nasdaq US Biotech.. 2.48 % 0.00 %

N/A

USD 0.52B
IBBQ Invesco Nasdaq Biotechnol.. 2.46 % 0.00 %

N/A

USD 0.04B
IBB iShares Biotechnology ETF 2.13 % 0.47 %

N/A

USD 7.60B
BIB ProShares Ultra Nasdaq Bi.. 1.76 % 0.95 %

N/A

USD 0.09B
ZHU:CA BMO Equal Weight US Healt.. 1.68 % 0.00 %

N/A

CAD 0.01B
FCTR 1.68 % 0.00 %

N/A

N/A
TAEQ 1.46 % 0.00 %

N/A

N/A
EWSP:SW iShares S&P 500 Equal Wei.. 0.23 % 0.00 %

N/A

USD 2.85B
FBT First Trust NYSE Arca Bio.. 0.00 % 0.57 %

N/A

N/A
FLAG 0.00 % 1.52 %

N/A

N/A
BTEC 0.00 % 0.42 %

N/A

N/A
HWF:CA 0.00 % 0.00 %

N/A

N/A
BTEC:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEK:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
BTEE:LSE iShares Nasdaq US Biotech.. 0.00 % 0.00 %

N/A

N/A
RYH 0.00 % 0.40 %

N/A

N/A
XT iShares Exponential Techn.. 0.00 % 0.47 %

N/A

N/A
ZUH:CA BMO Equal Weight US Healt.. 0.00 % 0.39 %

N/A

CAD 0.27B
ZGEN:CA 0.00 % 0.00 %

N/A

N/A
MRNS:LSE -299.96 % 0.00 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (OTCQB - U.S. Registered)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 23.10% 80% B- 85% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 23.10% 80% B- 85% B
Trailing 12 Months  
Capital Gain -0.45% 70% C- 52% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.45% 70% C- 50% F
Trailing 5 Years  
Capital Gain 736.41% 97% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 736.41% 97% N/A 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 130.87% 93% A 96% N/A
Dividend Return 130.87% 93% A 96% N/A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 221.82% 12% F 7% C-
Risk Adjusted Return 59.00% 96% N/A 85% B
Market Capitalization 0.02B 100% F 98% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative earnings

The company had negative total earnings in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector